Neuphoria Therapeutics Inc. Net Income (Loss) Attributable to Parent, Diluted
Neuphoria Therapeutics Inc. (NEUP) reported Net Income (Loss) Attributable to Parent, Diluted of -$3.52 million for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-17.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-02-17
- Neuphoria Therapeutics Inc. net income (loss) attributable to parent, diluted for the quarter ending 2025-12-31 was -$3.52M.
- Neuphoria Therapeutics Inc. net income (loss) attributable to parent, diluted for the quarter ending 2025-03-31 was $11.26M.
- Neuphoria Therapeutics Inc. net income (loss) attributable to parent, diluted for the quarter ending 2024-12-31 was -$2.82M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month |
|---|---|---|---|
| 2025-12-31 | -$3.52M 10-Q · filed 2026-02-17 | -$9.03M 10-Q · filed 2026-02-17 | |
| 2025-03-31 | $11.26M 10-Q · filed 2025-05-20 | $8.44M derived: sum of 2 quarters · filed 2026-02-17 | $5.74M 10-Q · filed 2025-05-20 |
| 2024-12-31 | -$2.82M 10-Q · filed 2026-02-17 | -$6.60M 10-Q · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |